Cannabis and COVID UK - Long Covid, Evidence, Guide

Cannabis and COVID UK: Understanding Long COVID, Evidence, and Your Guide
The relationship between cannabis and COVID-19 remains a topic of significant scientific and public interest throughout the UK. As Long COVID continues to affect hundreds of thousands of British citizens, many are exploring alternative therapeutic approaches, including cannabis-based treatments. This comprehensive guide examines the current evidence, provides practical information, and outlines what UK residents need to know about cannabis in relation to COVID-19 and Long COVID symptoms.

What is Long COVID and How Prevalent is it in the UK?
Long COVID, also referred to as Post-COVID syndrome or Long COVID syndrome, describes persistent symptoms that continue for weeks or months following the initial COVID-19 infection. According to the Office for National Statistics, approximately 1.9 million people in the UK reported Long COVID symptoms in 2026, with millions more experiencing milder forms of the condition.

Common Long COVID symptoms include fatigue, breathlessness, brain fog, joint pain, headaches, and psychological symptoms such as anxiety and depression. The severity and duration of these symptoms vary significantly between individuals, making treatment approaches highly personalised.

The Current Scientific Evidence on Cannabis and COVID

Research into cannabis COVID UK interactions is still in its early stages, though several preliminary studies suggest potential therapeutic benefits. A 2021 study published in Nature suggested that specific cannabinoid compounds might interact with the virus, though this research required further substantiation through clinical trials.

More importantly for Long COVID patients, evidence supports cannabis’s role in managing several symptoms associated with the condition:

Pain Management: Multiple clinical studies demonstrate cannabinoids’ effectiveness in reducing chronic pain. Long COVID patients experiencing joint and muscle pain may find relief through targeted cannabis treatments.

Sleep Disturbance: Research from King’s College London identified sleep problems as a significant Long COVID symptom affecting quality of life. Cannabis, particularly strains high in cannabinol (CBN), may improve sleep quality.

Fatigue and Energy: While cannabis can cause lethargy in some users, low-dose treatments may help regulate energy levels and reduce debilitating fatigue experienced by many Long COVID patients.

Anxiety and Depression: The Mental Health Foundation reports that psychological symptoms complicate Long COVID for many patients. Cannabis containing balanced CBD to THC ratios may support mental wellbeing, though individual responses vary considerably.

Medical Cannabis in the UK: Legal Status and Access

Since 2018, cannabis-based medicinal products have been legal in the UK under specific circumstances. However, access remains restricted and highly regulated through the NHS and private clinics.

To access medical cannabis legally in the UK, patients typically must:

Demonstrate that conventional treatments have failed or proven unsuitable; obtain a prescription from a registered specialist consultant; meet specific clinical criteria established by NICE (National Institute for Health and Care Excellence); and maintain regular monitoring and review appointments.

The cost of private cannabis treatments ranges from £150 to £400 monthly, making accessibility a significant challenge for many Long COVID patients. NHS provision remains extremely limited, with very few areas offering cannabis prescriptions outside specialist centres.

Cannabis Products Available in the UK Market

Legal cannabis medicines available in the UK include whole-plant extracts, CBD isolates, and synthetic cannabinoids. Common prescription products include Sativex (nabiximols spray), Epidyolex (CBD liquid), and various cannabis flower prescriptions from licensed producers.

CBD products, available legally without prescription, have proliferated across UK retail markets. These typically contain less than 0.2% THC and are marketed for general wellness. However, quality and potency vary significantly between manufacturers, and consumers should seek products tested by independent laboratories.

Cannabis Strains and Long COVID Symptoms

Different cannabis strains produce varying therapeutic effects based on their cannabinoid and terpene profiles:

High-CBD Strains: Ideal for anxiety, inflammation, and pain without significant psychoactive effects. Strains like Charlotte’s Web and Harlequin contain 8-20% CBD with minimal THC.

Balanced Strains: Containing roughly equal THC and CBD (5-10% each), these may benefit patients experiencing multiple symptom clusters while minimising impairment.

CBN-Rich Strains: Particularly suitable for sleep disturbance, these strains develop CBN through careful storage or specific breeding.

Low-THC Strains: Allow symptomatic benefit whilst maintaining cognitive function and productivity, important considerations for Long COVID patients managing work and daily responsibilities.

Practical Guide: Using Cannabis Safely for Long COVID

Start Low and Go Slow: Begin with minimal doses, gradually increasing over weeks whilst monitoring effects. This approach minimises adverse reactions and identifies optimal therapeutic doses.

Choose Your Administration Method: Vaporisation provides rapid relief and avoids smoking-related respiratory risks. Oils and tinctures offer precise dosing control. Edibles provide longer-lasting effects but take 1-2 hours to work.

Track Your Symptoms: Maintain detailed records of dosing, timing, and symptom changes. This information proves invaluable when discussing treatment with healthcare providers.

Consider Drug Interactions: Cannabis may interact with certain medications. Discuss potential interactions with your GP or specialist, particularly if taking anticoagulants, sedatives, or immunosuppressants.

Monitor Mental Health: Some individuals experience anxiety or paranoia, particularly with THC-dominant products. If adverse psychological effects occur, discontinue use and consult healthcare professionals.

NHS and Medical Professional Support

The British Medical Association acknowledges cannabis’s potential therapeutic applications whilst emphasising the need for further research. Many Long COVID specialist services now engage with patients exploring cannabis options, though few actively prescribe.

NHS Long COVID clinics are expanding across UK regions. These specialist centres provide comprehensive assessment and personalised treatment recommendations, potentially including cannabis discussion. Contact your GP for local clinic referrals.

Important Considerations and Limitations

Cannabis should not replace evidence-based Long COVID treatments, including rehabilitation programmes, pacing strategies, and psychological support. Rather, it may complement conventional approaches for symptom management.

Pregnancy and breastfeeding women should avoid cannabis entirely due to potential developmental risks. Individuals with personal or family histories of psychotic disorders require careful assessment before use.

Driving whilst impaired by cannabis remains illegal and dangerous. Patients should understand their individual response before operating vehicles.

Future Research and Developments

Several UK research institutions are investigating cannabis’s role in COVID-19 and Long COVID management. Forthcoming clinical trials may clarify optimal cannabinoid ratios, dosing protocols, and patient populations most likely to benefit.

The Medical Research Council and UK Biobank continue collecting data on cannabis use patterns and health outcomes, potentially establishing clearer evidence bases for treatment recommendations.

Conclusion

Cannabis represents a potentially useful therapeutic tool for managing specific Long COVID symptoms, supported by growing scientific evidence and increasing medical acceptance across the UK. However, accessing legal, quality-assured cannabis products remains challenging for most patients. Anyone considering cannabis for Long COVID should consult healthcare professionals, start with low doses, and maintain realistic expectations about realistic outcomes. As research progresses, the UK’s approach to cannabis COVID treatments will likely evolve, offering patients expanded options for managing this debilitating condition.

Cannabis and COVID UK – Long Covid, Evidence, Guide